Clinical Trial

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2106 versus Tremfye®（Guselkumab） in healthy subjects after a single dose.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-06
minor Completion moved earlier: 2026-08-30 -> 2026-04-23 2026-08-06
Trial Details
NCT Number NCT07479576
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Healthy Participants
Enrollment 190 participants
Start Date 2025-11-10
Primary Completion 2026-04-23 (estimated)
Study Completion 2026-04-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-05